Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1

Interventions

aldesleukin 15Cyclophosphamide 15fludarabine phosphate 12fludarabine 11Interleukin-2 10Nivolumab 6Ipilimumab 6Temozolomide 5pembrolizumab 3Fluorouracil 3trametinib 2sonidegib 2dabrafenib 2binimetinib 2Whole-Body Irradiation 2Vemurafenib 2Tacrolimus 2Sodium Chloride 2Sirolimus 2Radiotherapy 2Radiation 2Peptides 2HhAntag691 2Gefitinib 2Dacarbazine 2Cyclosporine 2Cetuximab 2Capecitabine 2veliparib 1varlilumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Skin Neoplasms × Toll-Like Receptor 1 × Clear all
NCT01701674 2025-12-19

Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
13 enrolled 10 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡